What is the current stock price of Moleculin Biotech, Inc. (MBRX)?

As of the latest market data, Moleculin Biotech, Inc. (MBRX) is trading at $2.62. The stock has seen a gain of 2.75% today.

Does Moleculin Biotech, Inc. (MBRX) pay a dividend?

Based on current data, Moleculin Biotech, Inc. does not have a confirmed active dividend policy.

What is the market cap of Moleculin Biotech, Inc.?

The current market capitalization of Moleculin Biotech, Inc. (MBRX) is approximately unavailable.

MBRX

Moleculin Biotech, Inc.·Healthcare

2.62

2.745%(+0.07)

Market Closed

2.66

1.527%(+0.04)

After Hours

Last Updated: — ET

52W L: $1.7952W H: $28.60

MBRX NEWS

globenewswire.com

4d ago

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

Access the Moleculin CEO Corner here

prnewswire.com

Mar 27

Scalable Biotech Manufacturing Unlocks a $14B Market

/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to

globenewswire.com

Mar 23

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). This milestone triggers the final phase of preparation for the trial's interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.

globenewswire.com

Mar 19

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML).

globenewswire.com

Mar 17

Moleculin to Present at 38th Annual ROTH Conference

– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners

globenewswire.com

Mar 11

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Access the Moleculin CEO Corner here

Company Profile

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2016-06-02

Beta

1.67

Websitewww.moleculin.com↗